CAFERGOT
LOE ApproachingNDARECTALSUPPOSITORYPriority Review
Approved
Apr 1953
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
Priority Review
CAFERGOT by Novartis is clinical pharmacology ergotamine is an alpha adrenergic blocking agent with a direct stimulating effect on the smooth muscle of peripheral and cranial blood vessels and produces depression of central vasomotor centers. First approved in 1953.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CAFERGOT is a fixed-dose combination of ergotamine (a vasoconstrictor with alpha-adrenergic blocking and serotonin antagonist properties) and caffeine, formulated as a rectal suppository. It is indicated for acute migraine treatment, particularly in patients experiencing severe nausea/vomiting that prevents oral medication retention. The dual mechanism enhances cranial vasoconstriction while bypassing hepatic metabolism via the rectal route.
LOE Approaching
LOE-approaching product with limited commercial expansion opportunity; brand teams face defensive positioning and resource optimization.
Mechanism of Action
CLINICAL PHARMACOLOGY Ergotamine is an alpha adrenergic blocking agent with a direct stimulating effect on the smooth muscle of peripheral and cranial blood vessels and produces depression of central vasomotor centers. The compound also has the properties of serotonin antagonism. In comparison to…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Worked on CAFERGOT at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.